Table 3 Mentioned/reported use of SMBG in CVOTs
From: PDM-ProValue meets cardiovascular outcome trials in diabetes
| Â | SMBG reported on clinicaltrials.gov | SMBG mentioned in clinical study protocol | SMBG results reported in final publication |
|---|---|---|---|
DPP-4 inhibitors | |||
SAVOR-TIMI | No (NCT01107886) | Yes | No (6) |
EXAMINE | No (NCT00968708) | No | No (7) |
TECOS | No (NCT00790205) | No | No (8) |
CARMELINA | No (NCT01897532) | Yes | No (9) |
SGLT-2 inhibitors | |||
EMPA-REG OUTCOME | No (NCT01131676) | Yes | No (15) |
CANVAS | No (NCT01032629) | Yes | No (16) |
DECLARE-TIMI 58 | No (NCT01730534) | No | No (17) |
GLP-1 receptor agonist | |||
ELIXA | No (NCT01147250) | Yes | No (10) |
SUSTAIN-6 | No (NCT01720446) | No | No (12) |
LEADER | No (NCT01179048) | Yes | No (11) |
EXCSEL | No (NCT01144338) | Not determined | No (13) |
Harmony outcomes | No (NCT02465515) | No | No (14) |
Insulin | |||
DEVOTE | No (NCT01959529) | Yes | Yes (19) |